Janux Therapeutics, Inc. (NASDAQ:JANX – Get Rating) shares were down 6.6% on Friday . The stock traded as low as $14.48 and last traded at $14.74. Approximately 1,241 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 103,848 shares. The stock had previously closed at $15.79.
Analyst Upgrades and Downgrades
Separately, William Blair started coverage on Janux Therapeutics in a research report on Monday, November 14th. They issued an “outperform” rating for the company.
Janux Therapeutics Stock Down 7.8 %
The company has a market capitalization of $606.57 million, a P/E ratio of -9.97 and a beta of 1.33. The firm has a 50-day moving average price of $14.98 and a two-hundred day moving average price of $13.22.
Institutional Trading of Janux Therapeutics
About Janux Therapeutics
Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
- Get a free copy of the StockNews.com research report on Janux Therapeutics (JANX)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.